Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Tislelizumab + Lenvatinib + Carvedilol in Unresectable HCC With Cirrhotic Portal Hypertension
NCT07350070Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carvedilol in hepatocellular carcinoma (HCC), Portal Hypertension (PH), sponsored by Tongji Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
carvedilol
03
Conditions
hepatocellular carcinoma (HCC)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT07350070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350070.